CLL

“If I only have one tool to treat the disease, I will play with that tool in many different ways. But if I have access to four different tools, then I will give up tool (number) one if I don't feel it's working,” explained Dr. Mazyar Shadman of the Seattle Cancer Care Alliance, about his approach to treating high-risk chronic lymphocytic leukemia in an interview with CURE^®.
 

“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”
 

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.
 

In an interview with CURE®, Dr. Mazyar Shadman discussed the enormous variety of treatment preferences among patients with CLL and said that emphasis should be placed on treating each person according to their wishes.
 

There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.
 

Here is a list of the recent trial initiations that occurred within the cancer space in June.
 

Regulation changes could eliminate barriers to potentially lifesaving CAR-T cell immunotherapy for patients covered by Medicare or Medicaid.
 

From a study showing a popular cancer side effect management steroid decreasing the risk of death for patients in the hospital with COVID-19 to a new liquid biopsy test detecting lingering cancer in DNA, here’s what’s making the headlines in the cancer space this week.
 

Here is a roundup of the latest news and updates for patients with Chronic Lymphocytic Leukemia from CURE.

“The superior efficacy of venetoclax-obinutuzumab has been observed and maintained in the current follow up,” Dr. Othman Al-Sawaf, of University Hospital of Cologne in Germany, said during a pre-recording presentation at the 2020 ASCO Virtual Scientific Program.